Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week 52 in a pair of Phase III trials to treat neovascular age-related macular degeneration (AMD). However, the candidate led to a greater incidence of intraocular inflammation compared with Lucentis.

The news sent shares of Molecular Partners down CHF4.26 (19%) to CHF18.14 on Thursday...